Kriya Therapeutics, Inc.

At Kriya, we’re advancing scalable #AAV manufacturing to potentially make #genetherapies more accessible and support clinical development and commercialization. Today’s poster at the American Society of Gene & Cell Therapy’s Annual Meeting evaluates bioprocessing containers to optimize quality and consistency in AAV products, while allowing for process scalability. To learn more about our work on scalable manufacturing, view the abstract here: https://bit.ly/4ujd2dm #ASGCT2026

Quality is central to Kriya's fully-integrated platform. Our analytical development capabilities enable rigorous understanding and control of #AAV product quality. At the American Society of Gene & Cell Therapy’s Annual Meeting, we're presenting two posters highlighting the development of highly sensitive, precise assays to quantify low levels of residual host cell DNA and measure functional transgene expression in complex biological samples. https://bit.ly/4ujd2dm #ASGCT2026

Join us at the American Society of Gene & Cell Therapy Annual Meeting, where we’re presenting two posters highlighting our focal delivery approach to #genetherapies in chronic diseases, including #Type1Diabetes, #MASH, and #GeographicAtrophy. This approach supports the potential for targeted therapeutic delivery with favorable tolerability profiles. We also look forward to a presentation by Fatima Bosch, PhD, Scientific Advisory Board Member, on FGF21 #genetherapy for #metabolicdiseases on Wednesday, May 14. https://bit.ly/4ujd2dm #ASGCT2026

We are looking forward to #ASGCT2026. Tomorrow, our Co-Founder and Chief Gene Therapy Officer, J Fraser Wright, will be co-chairing an oral abstract session on May 12th focused on #AAV downstream manufacturing. Bringing together leaders across viral vector development, this session will explore advancements in vector processing. At Kriya, we’re committed to driving conversations toward more scalable, durable and reproducible #genetherapies. Learn more: https://bit.ly/4tfQpWn

We’re looking forward to the American Society of Gene & Cell Therapy’s Annual Meeting next month, where we’ll be presenting five abstracts highlighting continued progress across our integrated #genetherapy platform, with a focus on targeted delivery, product quality and scalable manufacturing. Our approach is designed to make #genetherapies accessible for more common chronic diseases, and these presentations reflect our commitment to continuously optimizing our platform as we advance five programs to clinical development. Learn more: https://bit.ly/48sqByY #ASGCT2026

Thank you to everyone who joined us at Advanced Technologies & Treatments for Diabetes (ATTD) 2026 for an engaging discussion on the potential of #genetherapy for the treatment of #Type1diabetes. The conversation highlighted how advances in gene therapy may play a meaningful role in the future treatment paradigm for chronic diseases — and underscored the importance of continued collaboration across science, medicine, the industry, and the community. We look forward to building on these conversations over the course of this year! #ATTD2026 

Join us today at the Advanced Technologies & Treatments for Diabetes (ATTD) 2026 where we’re hosting an industry symposium exploring the potential of #genetherapy for the treatment of #Type1diabetes. The session brings together global experts to discuss how gene therapy may fit into the future of #T1D care. #ATTD2026 🗓 Friday, March 13 | 17:15–18:45  📍 Hall 113

Learn more about the potential of #genetherapy for the treatment of #T1D at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). #ATTD2026 📍 ATTD 2026 | Industry Symposium  🗓 Friday, March 13 | 17:15–18:45 | Barcelona, Spain  📍 Hall 113 For program details: https://bit.ly/4b4KAnL

We’re excited to welcome Sachiyo Minegishi as Chief Financial Officer. Sachiyo is a seasoned biotech executive with deep experience in corporate development, financial strategy and commercialization. In her role, she’ll oversee execution of our corporate strategy, scale financial operations and support planning for commercialization as we advance multiple #genetherapies through the clinic. Join us in welcoming her to the team! Learn more here: https://bit.ly/49FpBbq

We’re excited to welcome Sachiyo Minegishi as Chief Financial Officer. Sachiyo is a seasoned biotech executive with deep experience in corporate development, financial strategy and commercialization. In her role, she’ll oversee execution of our corporate strategy, scale financial operations and support planning for commercialization as we advance multiple #genetherapies through the clinic. Join us in welcoming her to the team! Learn more here: https://bit.ly/49FpBbq